Use of bisphosphonates in prostate cancer: Current status
Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We he...
Main Authors: | Rishi Nayyar, Narmada P Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2007-01-01
|
Series: | Indian Journal of Urology |
Subjects: | |
Online Access: | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=1;spage=51;epage=54;aulast=Nayyar |
Similar Items
-
Bone Health Management in the Continuum of Prostate Cancer Disease
by: Ettickan Boopathi, et al.
Published: (2022-09-01) -
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01) -
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
by: Mark Clemons, et al.
Published: (2021-10-01) -
Management of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate
by: Narmada P Gupta, et al.
Published: (2013-01-01) -
Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
by: Evangelia Ioannidou, et al.
Published: (2021-09-01)